Group items tagged

Opella Healthcare, trading as Sanofi Consumer Healthcare, said it has entered into a dual partnership agreement with Alliance Healthcare and Phoenix Healthcare Distribution for the wholesale supply of its products to UK pharmacies. In effect from the start of February, the new dual partnership will ensure Sanofi Consumer Healthcare 'continues to provide its customers with exceptional customer service', the company said, adding that the increased efficiency will facilitate improved service levels and stock availability of Cialis Together, Allevia, Buscopan, Dulcolax and Phenergan to community pharmacies in the UK. "At Sanofi Consumer Healthcare we are committed to supporting the self-care agenda in the UK," Nick Linton, head of UK country operations, commented. "Making healthcare as simple as it should be to bring health and wellbeing to all is a key priority for us in 2024 and beyond. Our new wholesale model reflects our deep commitment to working as efficiently as possible in close partnership with pharmacists to shape a healthier future."

Opella Healthcare, trading as Sanofi Consumer Healthcare, recently signed a dual partnership agreement with Alliance Healthcare and Phoenix Healthcare Distribution for the wholesale supply of its consumer healthcare products to community pharmacies throughout the United Kingdom. The new dual pharmacy wholesale partnership model, which became effective on 1 February 2024, underscores Sanofi's commitment to delivering exceptional customer service to its customers, the company said in a press release. The groundbreaking collaboration is expected to enhance operational efficiency as part of the company's go-to-market model, facilitating improved service levels and stock availability of key products, including Cialis® Together, Allevia®, Buscopan®, Dulcolax®, and Phenergan, to community pharmacies in the UK. Nick Linton, head of UK country operations, Sanofi Consumer Healthcare, said that the company is committed to supporting the "self-care agenda" in the UK. "Making healthcare as simple as it should be to bring health and wellbeing to all is a key priority for us in 2024 and beyond," he commented.

French drugmaker Sanofi will make 30 of its treatments, including insulin, available on a not-for-profit basis in 40 lower-income countries in the first step of its plan to increase access to its medicines worldwide. The treatments will be provided under the new Impact brand, part of Sanofi's global health unit launched last year, which sits outside the commercial business. The plan also includes the $25 million Impact fund, which will go towards supporting local start-up healthcare businesses and providing training on using the medicines, Sanofi said. "There's a lot of noise at the moment from different companies jumping into this space… but investing in entrepreneurship, in the ecosystem, is a new thing," said Jon Fairest, who heads the global health unit. The treatments available are on the World Health Organization's essential medicines list, and insulin in particular has been singled out by the UN agency as a life-saving medicine for diabetics that is difficult to access in many lower-income countries, where the burden of disease is growing.

Thornton & Ross is all set to expand its consumer healthcare offering by acquiring the well-established Opticrom eye-drops brand from Sanofi in the UK. Opticrom forms part of a wider transaction between Thornton & Ross' parent group, STADA, and Sanofi for eight local consumer healthcare brands across several countries, including Belgium, Germany, Hungary, Spain and the UK. The transaction will be financed with a combination of cash on balance sheet and existing facilities, and is scheduled to close in the fourth quarter of 2023, subject to customary approvals of relevant regulatory authorities. Opticrom Allergy 10ml bottle and 20 single doses for itchy, watery, red and inflamed eyes can be found behind the pharmacy counter, while Opticrom Hayfever 10ml bottle is available to purchase via self-selection to soothe and relieve eye symptoms of hayfever. These non-prescription medicines contain 20 mg/1ml sodium cromoglicate (2.0% w/v) and offer relief within 2 minutes.